Clinical Trial SuccessThe phase 2 EMBOLD trial results give high confidence that relutrigine is a real drug, as five out of 16 EMBOLD participants achieved complete seizure freedom for at least 28 days.
Pipeline PotentialPRAX is seen as undervalued given its multiple pipeline programs in the clinic.
Safety ProfileRelutrigine was generally well-tolerated in a severe, heavily treated population, and there were no cases of downward dose titration.